Professor Andrew Scott has made significant contributions to science and medicine through the discovery of novel therapeutic antibodies that are impacting on cancer patient outcomes, and the development of evidence for positron emission tomography (PET) that has led to the approval of multiple Medicare clinical indications for accurately staging cancer patients. He has provided leadership of scientific and medical professional organisations and in public education. Professor Scott is recognised Internationally for his research and clinical expertise, and for advocacy of molecular imaging and therapy, reflected by his recent election as President of the World Federation of Nuclear Medicine and Biology.